|
|
Volumn 17, Issue 3, 1999, Pages 237-240
|
|
Drug approval in Europe
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ARCITUMOMAB;
ARCITUMOMAB TC 99M;
BETA1A INTERFERON;
BLOOD CLOTTING FACTOR 7;
DESULFATOHIRUDIN;
DIPHTHERIA PERTUSSIS TETANUS VACCINE;
HEPATITIS A HEPATITIS B VACCINE;
IGOVOMAB;
IMIGLUCERASE;
INDIMACIS 125;
INSULIN LISPRO;
INTERFERON BETA SERINE;
INTERLEUKIN 2 RECEPTOR ANTIBODY;
LEPIRUDIN;
LEUKO SCAN;
MONOCLONAL ANTIBODY;
PRIMAVAX;
RECOMBINANT BLOOD CLOTTING FACTOR 7A;
RECOMBINANT BLOOD CLOTTING FACTOR 9;
RECOMBINANT ERYTHROPOIETIN;
RECOMBINANT FOLLITROPIN;
RECOMBINANT HUMAN INSULIN;
RETEPLASE;
RITUXIMAB;
SARUPLASE;
SULESOMAB;
UNCLASSIFIED DRUG;
VOTUMUMAB;
CENTRALIZATION;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG MARKETING;
EUROPE;
LAW;
PRIORITY JOURNAL;
REVIEW;
BIOTECHNOLOGY;
DRUG APPROVAL;
EFFICIENCY, ORGANIZATIONAL;
EUROPE;
|
|
EID: 0033061856
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/6977 Document Type: Review |
|
Times cited : (4)
|
|
References (1)
|
